Impact of type 1 diabetes mellitus and sitagliptin treatment on the neuropeptide Y system of rat retina
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Impact of type 1 diabetes mellitus and sitagliptin treatment on the neuropeptide Y system of rat retina. / Campos, Elisa J.; Martins, João; Brudzewsky, Dan; Correia, Sandra; Santiago, Ana R.; Woldbye, David P.D.; Ambrósio, António F.
In: Clinical and Experimental Ophthalmology, Vol. 46, No. 7, 2018, p. 783-795.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Impact of type 1 diabetes mellitus and sitagliptin treatment on the neuropeptide Y system of rat retina
AU - Campos, Elisa J.
AU - Martins, João
AU - Brudzewsky, Dan
AU - Correia, Sandra
AU - Santiago, Ana R.
AU - Woldbye, David P.D.
AU - Ambrósio, António F.
PY - 2018
Y1 - 2018
N2 - Background: Neuropeptide Y (NPY) is a neuromodulator that is expressed in the retina. Increasing evidence suggests that NPY has pronounced anti-inflammatory effects, which might depend on the inhibition of dipeptidyl-peptidase-IV (DPP-IV). The aim of this study was to investigate the impact of type 1 diabetes mellitus (DM) and sitagliptin, a DPP-IV inhibitor, on the NPY system in the retina using an animal model. Methods: Type 1 DM was induced in male Wistar rats by an intraperitoneal injection of streptozotocin. Starting 2weeks after DM onset, animals were treated orally with sitagliptin (5mg/kg.day) for 2weeks. The expression of NPY and NPY receptors (Y1, Y2 and Y5 receptors) was measured by quantitative polymerase chain reaction, Western blot and/or enzyme-linked immunosorbent assay. The immunoreactivity of NPY and NPY receptors was evaluated by immunohistochemistry, and the [35S]GTPγS binding assay was used to assess the functional binding of NPY receptors. Results: DM decreased the mRNA levels of NPY in the retina, as well as the protein levels of NPY and Y5 receptor. No changes were detected in the localization of NPY and NPY receptors in the retina and in the functional binding of NPY to all receptors. Sitagliptin alone reduced retinal NPY mRNA levels. The effects of DM on the NPY system were not affected by sitagliptin. Conclusion: DM modestly affects the NPY system in the retina and these effects are not prevented by sitagliptin treatment. These observations suggest that DPP-IV enzyme is not underlying the NPY changes detected in the retina induced by type 1 DM.
AB - Background: Neuropeptide Y (NPY) is a neuromodulator that is expressed in the retina. Increasing evidence suggests that NPY has pronounced anti-inflammatory effects, which might depend on the inhibition of dipeptidyl-peptidase-IV (DPP-IV). The aim of this study was to investigate the impact of type 1 diabetes mellitus (DM) and sitagliptin, a DPP-IV inhibitor, on the NPY system in the retina using an animal model. Methods: Type 1 DM was induced in male Wistar rats by an intraperitoneal injection of streptozotocin. Starting 2weeks after DM onset, animals were treated orally with sitagliptin (5mg/kg.day) for 2weeks. The expression of NPY and NPY receptors (Y1, Y2 and Y5 receptors) was measured by quantitative polymerase chain reaction, Western blot and/or enzyme-linked immunosorbent assay. The immunoreactivity of NPY and NPY receptors was evaluated by immunohistochemistry, and the [35S]GTPγS binding assay was used to assess the functional binding of NPY receptors. Results: DM decreased the mRNA levels of NPY in the retina, as well as the protein levels of NPY and Y5 receptor. No changes were detected in the localization of NPY and NPY receptors in the retina and in the functional binding of NPY to all receptors. Sitagliptin alone reduced retinal NPY mRNA levels. The effects of DM on the NPY system were not affected by sitagliptin. Conclusion: DM modestly affects the NPY system in the retina and these effects are not prevented by sitagliptin treatment. These observations suggest that DPP-IV enzyme is not underlying the NPY changes detected in the retina induced by type 1 DM.
KW - Diabetes
KW - Neuropeptide Y system
KW - Retina
KW - Sitagliptin
U2 - 10.1111/ceo.13176
DO - 10.1111/ceo.13176
M3 - Journal article
C2 - 29442423
AN - SCOPUS:85043287395
VL - 46
SP - 783
EP - 795
JO - Clinical and Experimental Ophthalmology
JF - Clinical and Experimental Ophthalmology
SN - 1442-6404
IS - 7
ER -
ID: 193285176